(1R,2S)-2-[(2,3-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S)-2-[(2,3-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• 化学式: C₁₄H₁₅Cl₂NO₃
• 分子量: 316.2
• InChiKey: YWMOHGQQVHRBJF-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
  申请人：Department of Health and Human Services The United States of America, as represented by the Secretary,

  公开号：US20160151350A1

  公开（公告）日：2016-06-02

  Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
• US9782399B2
  申请人：——

  公开号：US9782399B2

  公开（公告）日：2017-10-10
• [EN] PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME<br/>[FR] COMPOSITIONS PHARMACEUTIQUES QUI INHIBENT LA RÉGULATION, À MÉDIATION PAR FKBP52, DE LA FONCTION DE RÉCEPTEUR DES ANDROGÈNES ET MÉTHODES D'UTILISATION DE CELLES-CI
  申请人：US HEALTH

  公开号：WO2011034834A2

  公开（公告）日：2011-03-24

  Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
• [EN] FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUE D'UN AGENT DE CIBLAGE DE FKBP52
  申请人：US HEALTH

  公开号：WO2014151413A2

  公开（公告）日：2014-09-25

  Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and/or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography/tandem mass spectrometry (LC/MS/MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided.